摘要
近年来,非酒精性脂肪性肝炎(NASH)在流行病学、发病机理和确定治疗靶点等方面取得了稳步进展,但在治疗药物开发领域却进展缓慢.本文综述了生活方式干预、手术方法、肠道微生物群和药物治疗在治疗NASH方面的进展,重点关注胰岛素增敏剂、抗氧化剂、降胆固醇药物、甲状腺激素类似物、肠促胰岛素和细胞因子等药物对治疗NASH的作用,以期为未来治疗NASH提供更多的方法和选择.
Abstract
In recent years,steady progress has been made in the epidemiology,pathogenesis,and therapeutic targets of nonalcoholic steatohepatitis(NASH),while there has been slow progress in the field of therapeutic drug development.This article reviews the advances in lifestyle intervention,surgical methods,gut microbiota,and drugs in the treatment of NASH,especially the role of insulin sensitizers,antioxidants,cholesterol-lowering drugs,thyroid hormone mimetics,incretins,and cytokines in the treatment of NASH,in order to provide more methods and options for the treatment of NASH in the future.
国家科技期刊平台
NSTL
万方数据